SCHEMBL401258

SCHEMBL401258

CC(O)CC([NH])=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL42260 0.78
SCHEMBL2775806 0.73 CYP2C19 (0.44)
SCHEMBL11210311 0.73
SCHEMBL1031930 0.73
SCHEMBL276115 0.73
SCHEMBL1766467 0.73
SCHEMBL4603998 0.73
SCHEMBL6667335 0.73
(R)-3-Hydroxybutanoate SCHEMBL1533862 0.71 SLC22A6 (0.56)
SCHEMBL3364238 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110206772-A1 POLYSACCHARIDE COMPOSITION AND METHODS OF ISOLATION OF THE EMULSION STABILIZING CATIONIC POLYELECTROLYTIC POLYSACCHARIDE TRUSTEES OF TUFTS COLLEGE (US) 2011-08-25 US claimed
WO-2009155059-A2 POLYSACCHARIDE COMPOSITION AND METHODS OF ISOLATION OF THE EMULSION STABILIZING CATIONIC POLYELECTROLYTIC POLYSACCHARIDE TRUSTEES OF TUFTS COLLEGE (US) 2009-12-23 WO claimed
US-20190134052-A1 DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR NOVARTIS AG (CH) 2019-05-09 US disclosed
US-9452994-B2 Manufacturing process for pyrimidine derivatives NOVARTIS AG (CH) 2016-09-27 US disclosed
US-20160251334-A1 MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES FLUBACHER DIETMAR (DE) 2016-09-01 US disclosed
EP-3040333-A1 CRYSTALLINE FORMS OF 5-(2,6-DI-4-MORPHOLINYL-4-PYRIDMIDINYL)-4-TRIFLUOROMETHYLPYRIDIN-2-AMINE, A PIK3 INHIBITOR Novartis AG (CH) 2016-07-06 EP disclosed
US-9359326-B2 Manufacturing process for pyrimidine derivatives NOVARTIS AG (CH) 2016-06-07 US disclosed
US-9181215-B2 Manufacturing process for pyrimidine derivatives NOVARTIS AG (CH) 2015-11-10 US disclosed
US-20150232446-A1 MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2015-08-20 US disclosed
EP-2295402-B1 Antibacterial agents UNIV WASHINGTON (US) 2015-08-12 EP disclosed
US-20150141426-A1 DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR NOVARTIS PHARMACEUTICALS CORPORATION 2015-05-21 US disclosed
WO-2004060308-A2 THIOSEMICARBAZONES AS ANTI-VIRALS AND IMMUNOPOTENTIATORS CHIRON CORPORATION (US) 2004-07-22 WO disclosed
WO-2004048365-A1 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER CHIRON CORPORATION (US) 2004-06-10 WO disclosed
US-20040077707-A1 Pyrrole based inhibitors of glycogen synthase kinase 3 NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2004-04-22 US disclosed
WO-2004018455-A1 PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 CHIRON CORPORATION (US) 2004-03-04 WO disclosed
EP-0701998-B1 Process for production of tertiary n-alkenyl carboxylic acid amide NIPPON CATALYTIC CHEM IND (JP) 1998-07-29 EP disclosed
US-5625076-A Catalyst for production of tertiary N-alkenyl carboxylic acid amide, and process for production of tertiary N-alkenyl carboxylic acid amide using said catalyst NIPPON SHOKUBAI CO., LTD. (JP) 1997-04-29 US disclosed
EP-0701998-A1 Catalyst for production of tertiary n-alkenyl carboxylic acid amide, and process for production of tertiary n-alkenyl carboxylic acid amide using said catalyst NIPPON SHOKUBAI CO., LTD. (JP) 1996-03-20 EP disclosed
US-4329454-A Cephalosporin compounds ELI LILLY AND COMPANY (US) 1982-05-11 US disclosed
US-4144391-A REPLACING AN ACETOXY GROUP BY A SULFUR NUCLEOPHILE ELI LILLY AND COMPANY (US) 1979-03-13 US disclosed